Tata India Pharma & Healthcare Fund-Direct Plan-Growth
Tata Asset Management Limited · Direct Plan · Growth
Fund overview
0.25% on or before 30D
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹5,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹5,000 | ₹5,631 | +631 |
| 3 Years | ₹5,000 | ₹7,142 | +2,142 |
| 5 Years | ₹5,000 | ₹9,058 | +4,058 |
Calculated using the fund's annualised return since inception (12.6% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
42 securitiesTop 10 holdings make up 46.8% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 7.99% |
| Abbott India Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 5.94% |
| Healthcare Global Enterprises Ltd | Healthcare Services | Small Cap | 5.92% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 5.68% |
| Dr. Reddys Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.65% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 4.36% |
| Rainbow Children'S Medicare Ltd | Healthcare Services | Small Cap | 4.30% |
| Cipla Ltd | Pharmaceuticals & Biotechnology | Large Cap | 4.22% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Large Cap | 3.76% |
| Max Healthcare Institute Ltd | Healthcare Services | Mid Cap | 3.71% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹1,511 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹1,507 Cr
Exit load, stamp duty & tax
28-Dec-15
0.25% on or before 30D
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | 15.44% |
| Beta | 0.91 |
| Sharpe Ratio | 2.76 |
| Sortino Ratio | 0.24 |
| Treynor Ratio | 0.47 |
| Jensen's Alpha | 5.20 |
| Information Ratio | 0.17 |
| R-Squared | 96.07% |
| Max Drawdown | -3.66% |
| Upside Capture | 99.76% |
| Downside Capture | 77.41% |
Fund management
Scheme Details
Investment objective
Investment Objective Of The Scheme Is To Provide Long Term Capital Appreciation By Investing Predominantly In Equity/Equity Related Instruments Of The Companies In The Pharma&Healthcare Sectors In India. However, There Is No Assurance Or Guarantee That The Investment Objective Of The Scheme Will Be Achieved. The Scheme Does Not Assure Or Guarantee Any Returns.
Fund house
Tata Asset Management Limited
Frequently asked questions
What is the NAV of Tata India Pharma & Healthcare Fund-Direct Plan-Growth?
The NAV of Tata India Pharma & Healthcare Fund-Direct Plan-Growth is ₹36.17 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by Tata India Pharma & Healthcare Fund-Direct Plan-Growth?
The expense ratio charged by Tata India Pharma & Healthcare Fund-Direct Plan-Growth is 1.07%.
What is the Min. SIP of Tata India Pharma & Healthcare Fund-Direct Plan-Growth?
The minimum SIP investment in Tata India Pharma & Healthcare Fund-Direct Plan-Growth is ₹100 per month.
What is the Min. Lumpsum of Tata India Pharma & Healthcare Fund-Direct Plan-Growth?
The minimum lumpsum investment in Tata India Pharma & Healthcare Fund-Direct Plan-Growth is ₹5,000.
What is the Exit Load of Tata India Pharma & Healthcare Fund-Direct Plan-Growth?
The exit load for Tata India Pharma & Healthcare Fund-Direct Plan-Growth is: 0.25% on or before 30D
.svg){kind=small}